Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*
British Journal of Dermatology2022Vol. 187(2), pp. 234–243
Citations Over TimeTop 10% of 2022 papers
Cosimo Di Raimondo, Belén Rubio-González, Joycelynne Palmer, Dennis D. Weisenburger, Jasmine Zain, Xiwei Wu, Zhen Han, Steven T. Rosen, Joo Y. Song, Christiane Querfeld
Abstract
These findings demonstrate the existence of a complex immunoregulatory microenvironment in CTCL and support the development of immunotherapies targeting ICOS and PD-L1 in advanced disease.
Related Papers
- → ADVANCES IN THE MANAGEMENT OF CUTANEOUS T-CELL LYMPHOMA(1998)16 cited
- → Cutaneous T-cell lymphoma (mycosis fungoides)(1996)9 cited
- → Efficacy of chlormethine gel in patients with stage I–IIA mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): re-analysis of a randomized phase 2 study(2019)
- → Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study(2019)
- → Unspecified skin peripheral T-cell lymphoma: diagnostic difficulties(2020)